Showing results (191-200 of 221) with videos related to
Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 ImmunityBrian Orr, Haider Mahdi, Yusi Fang, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the scienceRachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.Brachytherapy|May 2, 2025
Twice daily template-based interstitial brachytherapy for gynecologic cancers: What is the optimal dose?Ria Mulherkar, David Grimm, Paniti Sukumvanich, et al.Gynecologic Oncology Reports|October 17, 2022
Clinical factors associated with failed sentinel lymph node mapping in endometrial cancerAlison A Garrett, Alyssa Wield, Brigid Mumford, et al.The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.The Lancet. Oncology|December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialRodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.Gynecologic Oncology|May 12, 2026
Endometriosis and ovarian cancer riskGiorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.Journal of Radiosurgery and SBRT|April 26, 2021
Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experienceTimothy D Smile, Chandana A Reddy, George Qiao-Guan, et al.Pageof 23